0001615219-15-000047.txt : 20150901 0001615219-15-000047.hdr.sgml : 20150901 20150901172036 ACCESSION NUMBER: 0001615219-15-000047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150831 FILED AS OF DATE: 20150901 DATE AS OF CHANGE: 20150901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Flex Pharma, Inc. CENTRAL INDEX KEY: 0001615219 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465087339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 BOYLSTON STREET STREET 2: 24TH FLOOR CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-874-1821 MAIL ADDRESS: STREET 1: 800 BOYLSTON STREET STREET 2: 24TH FLOOR CITY: BOSTON STATE: MA ZIP: 02199 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Westphal Christoph H CENTRAL INDEX KEY: 0001291961 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36812 FILM NUMBER: 151088022 MAIL ADDRESS: STREET 1: C/O ALNYLAM PHARMACEUTICALS, INC STREET 2: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 wf-form4_144114242638458.xml FORM 4 X0306 4 2015-08-31 0 0001615219 Flex Pharma, Inc. FLKS 0001291961 Westphal Christoph H C/O FLEX PHARMA, INC. 800 BOYLSTON STREET BOSTON MA 02199 1 1 1 0 President and CEO Common Stock 2015-08-31 4 P 0 887 12.495 A 3912328 D Common Stock 2697264 I By Longwood Fund II. L.P. The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2015. Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund II, L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose. /s/ Robert Hadfield, Attorney-in-Fact 2015-09-01